OncoMatch/Clinical Trials/NCT02961101
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Is NCT02961101 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Anti-PD-1 antibody and Decitabine for malignancies multiple.
Treatment: Anti-PD-1 antibody · Decitabine · Chemotherapy — The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,000/μL; Platelet count ≥ 70,000/µL
Kidney function
Serum creatinine ≤ 1.5 x ULN
Liver function
Serum bilirubin level ≤ 1.5 x ULN; ALT/AST ≤ 2.5 x ULN
Cardiac function
adequate heart function
adequate bone marrow, live, renal, lung and heart functions. Absolute neutrophil count ≥ 1,000/μL. Platelet count ≥ 70,000/µL. Serum bilirubin level ≤ 1.5 x ULN. Serum creatinine ≤ 1.5 x ULN. ALT and AST ≤ 2.5 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02961101 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 12 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify